Overview

Pifenidone Prophylactic Therapy for Radiation Lung Injury in Patients Who Have Previously Received Immune Checkpoint Inhibitors

Status:
Recruiting

Trial end date:
2025-09-01

Target enrollment:

Participant gender:

Summary

Patients with advanced lung cancer who have previously received immunocheckpoint inhibitor therapy, undergone chest radiation therapy again have developed radiation induced lung injury. Pirfenidone has anti-inflammatory and anti fibrosis effects. This study is intended to evaluate the effectiveness of pirfenidone combined with radiotherapy in the prevention of radiation pneumonitis.

Phase:

Phase 2

Details

Lead Sponsor:

Hubei Cancer Hospital

Treatments:

Pirfenidone